Telix Pharmaceuticals’ Pixclara: A New Frontier in Glioma Imaging
Diagnosing the progression of glioma—a challenging form of brain cancer—often involves a hard clinical puzzle: distinguishing between actual tumor growth and treatment-related changes. Telix Pharmaceuticals is working to solve this problem with Pixclara (TLX101-CDx), an investigational PET imaging agent designed to provide clearer insights into brain cancer behavior.
- What it is: Pixclara (18F-floretyrosine or 18F-FET) is a targeted PET imaging agent for glioma.
- Current Status: The FDA has accepted a resubmitted New Drug Application (NDA).
- Critical Date: The FDA’s PDUFA target action date is set for September 11, 2026.
- Goal: To help clinicians differentiate between recurrent glioma and treatment-induced changes in adult and pediatric patients.
Understanding the Require for Advanced Glioma Imaging
For patients fighting glioma, the post-treatment phase is often fraught with uncertainty. Standard imaging can sometimes struggle to tell the difference between a tumor that is growing back (recurrence) and the inflammation or scarring caused by previous therapy. This ambiguity can lead to delays in treatment or unnecessary interventions.
Although amino acid PET imaging is already included in European and U.S. Guidelines, there hasn’t been an FDA-approved targeted PET agent specifically for brain cancer imaging in the United States. Pixclara aims to fill this gap, offering a more precise tool for the characterization of progressive or recurrent glioma.
The Regulatory Journey of Pixclara
The path to FDA approval for Pixclara has involved several critical milestones and setbacks:
Prompt Track Designation
In April 2024, the FDA granted Fast Track designation to TLX101-CDx. This status is designed to expedite the review of drugs that treat serious conditions and fill unmet medical needs, allowing for closer consultation between Telix and the agency.
The Initial Setback and Resubmission
The process wasn’t without hurdles. On April 28, 2025, the FDA denied the initial application, stating that additional clinical evidence was required before the agent could be approved. Yet, Telix remained committed to the product, eventually reaching an agreement with the FDA in September 2025 on a pathway for resubmitting the NDA.
Current Status and 2026 Timeline
As of April 10, 2026, the FDA has officially accepted the resubmitted NDA for Pixclara. The agency has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 11, 2026. This date marks the deadline by which the FDA intends to complete its review and provide a decision on whether the agent can be marketed in the U.S.
Collaborations and Clinical Expertise
Telix hasn’t worked in isolation. The company maintains an exclusive research collaboration and data license agreement with the University of California, San Francisco (UCSF). UCSF is a leading center for clinical research into FET PET in neurological malignancies. This partnership allows Telix to use real-world clinical data to support the commercialization of the agent.
Frequently Asked Questions
What exactly is Pixclara?
Pixclara, also known as TLX101-Px or 18F-floretyrosine (18F-FET), is a radiopharmaceutical used in positron emission tomography (PET) scans to image gliomas.
Who will benefit from this imaging agent?
If approved, it’s expected to benefit both adult and pediatric patients by helping doctors distinguish between tumor progression and treatment-related changes.
When will we understand if it’s approved?
The FDA is expected to make a decision by September 11, 2026.
Looking Ahead
The potential approval of Pixclara represents a significant step forward in neuro-oncology. By providing a targeted way to visualize brain cancer, clinicians can make more informed decisions about patient care, potentially improving outcomes for those facing the complexities of glioma recurrence.
Related reading